GPR40: A therapeutic target for mediating insulin secretion (Review)

International Journal of Molecular Medicine

Volumn 30, Issue 6, 2012, Pages 1261-1266

  Feng, Xiao Tao ^a   Leng, Jing ^a   Xie, Zhen ^a   Li, Shuang Lei ^a   Zhao, Wei ^a   Tang, Qian Li ^a  

^a GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Free fatty acids; G protein coupled receptor; Insulinotropic reagent; Pancreatic cells; Type 2 diabetes

Indexed keywords

3 [2 FLUORO 4 [[[4' [(4 HYDROXY 1,1 DIOXIDOTETRAHYDRO 2H THIOPYRAN 4 YL) METHOXY] 2',6' DIMETHYLBIPHENYL 3 YL]METHYL)AMINO]PHENYL] PROPANOIC ACID; AMG 387; AMG 837; ANTIDIABETIC AGENT; ARGININE; ASPARAGINE; ASTRAGALUS MEMBRANACEUS EXTRACT; BERBERINE; CALCIUM CHANNEL L TYPE; COPTIS CHINENSIS EXTRACT; G PROTEIN COUPLED RECEPTOR 40; GINSENG EXTRACT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GW 9508; GW9508; HISTIDINE; INSULIN; INSULIN SENSITIZING AGENT; LINOLEIC ACID; LONG CHAIN FATTY ACID; LONICERA JAPONICA EXTRACT; PIOGLITAZONE; PLANT EXTRACT; PROTEIN KINASE C; REHMANNIAE RADIX EXTRACT; SCUTELLARIAE RADIX; SERINE; TAK 875; THIAZOLIDINE DERIVATIVE; THREONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ASTRAGALUS MEMBRANACEUS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL FUNCTION; CLINICAL PRACTICE; CONSTIPATION; COPTIS CHINENSIS; DRUG MEGADOSE; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; EXON; FRACTURE; GINSENG; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INTRON; LOADING DRUG DOSE; LONICERA JAPONICA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHMANNIA ROOT; REVIEW; RNA PROCESSING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOFURANS; BERBERINE; CLINICAL TRIALS, PHASE II AS TOPIC; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED; SULFONES;

EID: 84869468389     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1142     Document Type: Review

References (90)

1. Yang W, Lu J, Weng J, et al: Prevalence of diabetes among men and women in China. N Engl J Med 362: 1090-1101, 2010.
2. Davis TM, Peters KE, Bruce DG and Davis WA: Prevalence, incidence and prognosis of hepatobiliary disease in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. J Clin Endocrinol Metab 97: 1581-1588, 2012.
3. Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49: 1751-1760, 2000.
4. Sako Y and Grill V: A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127: 1580-1589, 1990. (Pubitemid 20315212)
5. Ayvaz G, Balos Törüner F, Karakoç A, et al: Acute and chronic effects of different concentrations of free fatty acids on the insulin secreting function of islets. Diabetes Metab 28: 3S7-3S12, 2002.
6. Schmidt J, Liebscher K, Merten N, et al: Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40. J Biol Chem 286: 11890-11894, 2011.
7. Kashyap S, Belfort R, Gastaldelli A, et al: A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52: 2461-2474, 2003. (Pubitemid 37210533)
8. Ritz-Laser B, Meda P, Constant I, et al: Glucose-induced preproinsulin gene expression is inhibited by the free fatty acid palmitate. Endocrinology 140: 4005-4014, 1999. (Pubitemid 30647095)
9. 2+ homeostasis in β-cells. Am J Physiol Endocrinol Metab 296: E690-E701, 2009.
10. Lai E, Bikopoulos G, Wheeler MB, et al: Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic beta-cells. Am J Physiol Endocrinol Metab 294: E540-E550, 2008. (Pubitemid 351355224)
11. Böni-Schnetzler M, Boller S, Debray S, et al: Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150: 5218-5229, 2009.
12. Tuo Y, Feng DD, Wang DF, et al: Long-term in vitro treatment of INS-1 rat pancreatic β-cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors. Clin Exp Pharmacol Physiol 39: 423-428, 2012.
13. Chawla A, Repa JJ, Evans RM and Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870, 2001. (Pubitemid 33101573)
14. Sawzdargo M, George SR, Nguyen T, et al: A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun 239: 543-547, 1997. (Pubitemid 27489000)
15. Brown AJ, Goldsworthy SM, Barnes AA, et al: The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278: 11312-11319, 2003. (Pubitemid 36792688)
16. Schnell S, Schaefer M and Schofl C: Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol 263: 173-180, 2007. (Pubitemid 44834553)
17. Miyauchi S, Hirasawa A, Ichimura A, et al: New frontiers in gut nutrient sensor research: free fatty acid sensing in the gastrointestinal tract. J Pharmacol Sci 112: 19-24, 2010.
18. Xiong Y, Miyamoto N, Shibata K, et al: Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci USA 101: 1045-1050, 2004. (Pubitemid 38160581)
19. Le Poul E, Loison C, Struyf S, et al: Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278: 25481-25489, 2003. (Pubitemid 36835299)
20. Ge H, Li X, Weiszmann J, et al: Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 149: 4519-4526, 2008.
21. Maslowski KM, Vieira AT, Ng A, et al: Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461: 1282-1286, 2009.
22. Hirasawa A, Tsumaya K, Awaji T, et al: Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90-94, 2005. (Pubitemid 40215843)
23. Oh DY, Talukdar S, Bae EJ, et al: GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698, 2010.
24. Kebede M, Alquier T, Latour MG, et al: The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57: 2432-2437, 2008.
25. Del Guerra S, Bugliani M, D'Aleo V, et al: G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis 20: 22-25, 2010.
26. Alquier T, Peyot ML, Latour MG, et al: Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58: 2607-2615, 2009.
27. Nagasumi K, Esaki R, Iwachidow K, et al: Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58: 1067-1076, 2009.
28. Houze JB, Zhu L, Sun Y, et al: AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett 22: 1267-1270, 2012.
29. Negoro N, Sasaki S, Ito M, et al: Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists. J Med Chem 55: 1538-1552, 2012.
30. Hara T, Hirasawa A, Ichimura A, et al: Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J Pharm Sci 100: 3594-3601, 2011.
31. Itoh Y and Hinuma S: GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol Res 33: 171-173, 2005. (Pubitemid 41799798)
32. Tomita T, Masuzaki H, Noguchi M, et al: GPR40 gene expression in human pancreas and insulinoma. Biochem Biophys Res Commun 338: 1788-1790, 2005. (Pubitemid 41643091)
33. Steneberg P, Rubins N, Bartoov-Shifman R, et al: The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 1: 245-258, 2005. (Pubitemid 43960613)
34. Bartoov-Shifman R, Ridner G, Bahar K, et al: Regulation of the gene encoding GPR40, a fatty acid receptor expressed selectively in pancreatic beta cells. J Biol Chem 282: 23561-23571, 2007. (Pubitemid 47311899)
35. Ridner G, Bartoov-Shifman R, Zalogin T, et al: Regulation of the GPR40 locus: towards a molecular understanding. Biochem Soc Trans 36: 360-362, 2008. (Pubitemid 351839332)
36. Winzell MS and Ahrén B: G-protein-coupled receptor and islet function-implications for treatment type 2 diabetes. Pharmacol Ther 116: 437-448, 2007. (Pubitemid 350116941)
37. Stoddart LA, Smith NJ and Millgan G: International Union of Pharmacology. LXXI. Free fatty acid receptor FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60: 405-417, 2008.
38. Tikhonova IG, Sum CS, Neumann S, et al: Bidirectional, iterative approach to the structural delineation of the functional 'chemoprint' in GPR40 for agonist recognition. J Med Chem 50: 2981-2989, 2007. (Pubitemid 47001241)
39. Morgan NG and Dhayal S: G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta cell. Biochem Pharmacol 78: 1419-1427, 2009.
40. Sum CS, Tikhonova IG, Neumann S, et al: Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 282: 29248-29255, 2007. (Pubitemid 350043382)
41. Lu SY, Jiang YJ, Zou JW, et al: Insight into analysis of interactions of GW9508 to wild-type and H86F and H137F GPR40: a combined QM/MM study and pharmacophore modeling. J Mol Graph Model 29: 818-825, 2011.
42. Ogawa T, Hirose H, Miyashita K, et al: GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism 54: 296-299, 2005.
43. Vettor R, Granzotto M, De Stefani D, et al: Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab 93: 3541-3550, 2008.
44. Briscoe CP, Tadayyon M, Andrews JL, et al: The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278: 11303-11311, 2003. (Pubitemid 36792687)
45. Itoh Y, Kawamata Y, Harada M, et al: Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173-176, 2003. (Pubitemid 36362750)
46. Kotarsky K, Nilsson NE, Flodgren E, et al: A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun 301: 406-410, 2003. (Pubitemid 36279253)
47. Yang M, Chisholm JW, Soelaiman S and Shryock JC: Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells. Mol Cell Endocrinol 315: 308-313, 2010.
48. Yazaki R, Kumagai N and Shibasaki M: Enantioselective synthesis of a GPR40 agonist AMG 837 via catalytic asymmetric conjugate addition of terminal alkyne to á,β-unsaturated thioamide. Org Lett 13: 952-955, 2011.
49. Yazaki R, Kumagai N and Shibasaki M: Cooperative activation of alkyne and thioamide functionalities; direct catalytic asymmetric conjugate addition of terminal alkynes to á,β-unsaturated thioamides. Chem Asian J 6: 1778-1790, 2011.
50. Walsh SP, Severino A, Zhou C, et al: 3-Substituted 3-(4-aryloxyaryl)- propanoic acids as GPR40 agonists. Bioorg Med Chem Lett 21: 3390-3394, 2011.
51. Zhang X, Yan G, Li Y, et al: DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacother 64: 647-651, 2010.
52. Hu H, He LY, Gong Z, et al: A novel class of antagonists for the FFAs receptor GPR40. Biochem Biophys Res Commun 390: 557-563, 2009.
53. Wu J, Sun P, Zhang X, et al: Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis. J Cell Biochem 113: 1152-1158, 2012.
54. Zhao Y, Song Y, Shen X and Liao J: Feasible synthesis of antagonist of GPR40 by constructing 2-thiouracil ring via acid mediated cyclization. Heterocycles 83: 1145-1151, 2011.
55. Stein DT, Esser V, Stevenson BE, et al: Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97: 2728-2735, 1996. (Pubitemid 26197087)
56. Tuei VC, Ha JS and Ha CE: Effects of human serum albumin complexed with free fatty acids on cell viability and insulin secretion in the hamster pancreatic β-cell line HIT-T15. Life Sci 88: 810-818, 2011.
57. Wang C, Tan H, Yu H, et al: Impairment of insulin action in non-obese, normal-glucose tolerant, first-degree relatives of Chinese type 2 diabetic patients. Diabetes Res Clin Pract 91: 67-71, 2011.
58. Lan H, Hoos LM, Liu L, et al: Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57: 2999-3006, 2008.
59. Tan CP, Feng Y, Zhou YP, et al: Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57: 2211-2219, 2008.
60. 2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 289: E670-E677, 2005.
61. Shapiro H, Shachar S, Sekler I, et al: Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 335: 97-104, 2005. (Pubitemid 41350767)
62. Latour MG, Alquier T, Oseid E, et al: GPR40 in necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56: 1087-1094, 2007. (Pubitemid 46525064)
63. + currents in primary cultured rat pancreatic beta-cells by linoleic acids. Endocrinology 147: 674-682, 2006.
64. Briscoe CP, Peat AJ, McKeown SC, et al: Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148: 619-628, 2006. (Pubitemid 43993052)
65. Mikami S, Kitamura S, Negoro N, et al: Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes. J Med Chem 55: 3756-3776, 2012.
66. Lin DC, Zhang J, Zhuang R, et al: AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 6: e27270, 2011.
67. Wu P, Yang L and Shen X: The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone. Biochem Biophys Res Commun 403: 36-39, 2010.
68. Meidute Abaraviciene S, Lundquist I, Galvanovskis J, et al: Palmitate-induced beta-cell dysfunction is associated with excessive NO production and is reversed by thiazolidinedione-mediated inhibition of GPR40 transduction mechanisms. PLoS One 3: e2182, 2008.
69. Singh S, Loke YK and Furberg CD: Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30: 2148-2153, 2007. (Pubitemid 47219440)
70. Mieczkowska A, Basle MF, Chappard D and Mabilleau G: Thiazolidinediones induced osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 287: 23517-23526, 2012.
71. Zhou C, Tang C, Chang E, et al: Discovery of 5-aryloxy-2,4- thiazolidinediones as potent GPR40 agonists. Bioorg Med Chem Lett 20: 1298-1301, 2010.
72. Yashiro H, Tsujihata Y, Takeuchi K, et al: The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther 340: 483-489, 2012.
73. Tsujihata Y, Ito R, Suzuki M, et al: TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339: 228-237, 2011.
74. Negoro N, Sasaki S, Mikami S, et al: Optimization of (2,3-dihydro-1- benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. J Med Chem 55: 3960-3974, 2012.
75. Naik H, Vakilynejad M, Wu J, et al: Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52: 1007-1016, 2012.
76. Araki T, Hirayama M, Hiroi S and Kaku K: GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 14: 271-278, 2012.
77. Burant CF, Viswanathan P, Marcinak J, et al: TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379: 1403-1411, 2012.
78. Xie W, Zhao Y and Zhang Y: Traditional chinese medicines in treatment of patients with type 2 diabetes mellitus. Evid Based Complement Alternat Med 2011: 726723, 2011.
79. Chao M, Zou D, Zhang Y, et al: Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients. Endocrine 36: 268-274, 2009.
80. Chen DS, Ke B, Huang YJ, et al: Effects of the modified linggui zhugan decoction (see text) combined with short-term very low calorie diets on glycemic control in newly diagnosed type 2 diabetics. J Tradit Chin Med 31: 185-188, 2011.
81. Cicero AF and Tartagni E: Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. Hosp Pract (Minneap) 40: 56-63, 2012.
82. Lou T, Zhang Z, Xi Z, et al: Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation 34: 659-667, 2011.
83. Gao N, Zhao TY and Li XJ: The protective effect of berberine on β-cell lipoapoptosis. J Endocrinol Invest 34: 124-130, 2011.
84. Ko BS, Choi SB, Park SK, et al: Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull 28: 1431-1437, 2005. (Pubitemid 41379694)
85. Rayasam GV, Tulasi VK, Sundaram S, et al: Identification of berberine as a novel agonist of fatty acid receptor GPR40. Phytother Res 24: 1260-1263, 2010.
86. Park SM, Hong SM, Sung SR, et al: Extracts of Rehmanniae radix, Ginseng radix and Scutellariae radix improve glucose-stimulated insulin secretion and beta-cell proliferation through IRS2 induction. Genes Nutr 2: 347-351, 2008. (Pubitemid 351447710)
87. Zhang Y and Liu D: Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic beta-cell viability and insulin secretory function. Eur J Pharmacol 670: 325-332, 2011.
88. Edfalk S, Steneberg P and Edlund H: Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280-2287, 2008.
89. 2+ signaling through activation of free fatty acid receptor GPR40. Neurobiol Dis 43: 465-472, 2011.
90. Nakamoto K, Nishinaka T, Matsumoto K, et al: Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res 1432: 74-83, 2012.